Download PDF
Thromb Haemost 2021; 121(10): 1376-1386
DOI: 10.1055/a-1346-3300
Atherosclerosis and Ischaemic Disease

Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial

Young-Hoon Jeong  ‡   *
1   Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea
2   Institute of the Health Sciences, Gyeongsang National University, Jinju, South Korea
,
Ju-Hyeon Oh‡   *
3   Division of Cardiology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea
,
Hyuck-Jun Yoon
4   Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea
,
Yongwhi Park
1   Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea
2   Institute of the Health Sciences, Gyeongsang National University, Jinju, South Korea
,
Jon Suh
5   Division of Cardiology, Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Bucheon, South Korea
,
Se-Whan Lee
6   Department of Cardiology, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea
,
Kyounghoon Lee
7   Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea
,
Jeong-Su Kim
8   Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea
,
Woo-Jung Chun
3   Division of Cardiology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea
,
Yong-Hwan Park
3   Division of Cardiology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea
,
Chang-Wook Nam
4   Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea
,
June-Hong Kim
8   Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea
,
Jong-Hwa Ahn
9   Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea
,
Seok-Jae Hwang
9   Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea
,
Jin-Yong Hwang
2   Institute of the Health Sciences, Gyeongsang National University, Jinju, South Korea
9   Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea
,
Udaya S. Tantry
10   Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, United States
,
Paul A. Gurbel
10   Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, United States
,
Eun-Seok Shin
11   Division of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
› Author Affiliations Funding This study was supported by research grants from the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science, ICT, and Future Planning (NRF-2015R1A5A2008833).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Compared with Caucasian patients, East Asian patients have the unique risk–benefit trade-off and different responsiveness to antithrombotic regimens. The aim of this study was to compare pharmacodynamic profile in East Asian patients with acute coronary syndromes (ACSs) treated with prasugrel standard-dose versus a de-escalation strategy. Before discharge, ACS patients with age <75 years or weight ≥60 kg (n = 255) were randomly assigned to the standard-dose (10-mg group) or de-escalation strategy (5-mg group or platelet function test [PFT]-guided group). After 1 month, VerifyNow P2Y12 assay-based platelet reactivity (P2Y12 reaction unit [PRU]) and bleeding episodes were evaluated. Primary endpoint was the percentage of patients with the therapeutic window (85 ≤ PRU ≤ 208). The 250 patients completed 1-month treatment. The percentage of patients within the therapeutic window was significantly lower in the 10-mg group (n = 85) compared with the 5-mg (n = 83) and PFT-guided groups (n = 82) (35.3 vs. 67.5 vs. 65.9%) (odds ratio [OR]: 3.80 and 3.54; 95% confidence interval [CI]: 2.01–7.21 and 1.87–6.69, respectively). Compared with the 10-mg group, the bleeding rate was tended to be lower with de-escalation strategies (35.3 vs. 24.1% vs. 23.2%) (hazard ratio [HR]: 0.58 and 0.55; 95% CI: 0.30–1.14 and 0.28–1.09, respectively). “PRU < 127” was the optimal cut-off for predicting 1-month bleeding events (area under the curve: 0.616; 95% CI: 0.543–0.689; p = 0.005), which criteria was significantly associated with early discontinuation of prasugrel treatment (HR: 2.00; 95% CI: 1.28–3.03; p = 0.001). In conclusion, compared with the standard-dose prasugrel, the prasugrel de-escalation strategy in East Asian patients presented with ACS showed a higher chance within the therapeutic window and a lower tendency toward bleeding episodes.

Registration URL: https://clinicaltrials.gov. Unique identifier:NCT01951001.

Keywords

acute coronary syndrome - prasugrel - East Asians - de-escalation strategy - platelet function test

* These authors contributed equally to this work.


Supplementary Material



Publication History

Received: 24 October 2020

Accepted: 02 January 2021

Accepted Manuscript online:
05 January 2021

Article published online:
03 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Collet JP, Thiele H, Barbato E. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42 (14) 1289-1367
    CrossrefPubMedGoogle Scholar
  • 2 Valgimigli M, Bueno H, Byrne RA. et al; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
    CrossrefPubMedGoogle Scholar
  • 3 Antman EM, Wiviott SD, Murphy SA. et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51 (21) 2028-2033
    CrossrefPubMedGoogle Scholar
  • 4 Urban P, Mehran R, Colleran R. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019; 140 (03) 240-261
    CrossrefPubMedGoogle Scholar
  • 5 Angiolillo DJ, Rollini F, Storey RF. et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017; 136 (20) 1955-1975
    CrossrefPubMedGoogle Scholar
  • 6 Sibbing D, Aradi D, Alexopoulos D. et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 2019; 12 (16) 1521-1537
    CrossrefPubMedGoogle Scholar
  • 7 Levine GN, Jeong YH, Goto S. et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11 (10) 597-606
    CrossrefPubMedGoogle Scholar
  • 8 Huo Y, Jeong YH, Gong Y. et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Sci Bull (Beijing) 2019; 64: 166-179
    CrossrefPubMedGoogle Scholar
  • 9 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Small DS, Kothare P, Yuen E. et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010; 66 (02) 127-135
    CrossrefPubMedGoogle Scholar
  • 11 Small DS, Li YG, Ernest II CS. et al. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. J Clin Pharmacol 2011; 51 (03) 321-332
    CrossrefPubMedGoogle Scholar
  • 12 Saito S, Isshiki T, Kimura T. et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014; 78 (07) 1684-1692
    CrossrefPubMedGoogle Scholar
  • 13 Menichelli M, Neumann FJ, Ndrepepa G. et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: results from a randomized trial. Ann Intern Med 2020; 173 (06) 436-444
    CrossrefPubMedGoogle Scholar
  • 14 Kim HS, Kang J, Hwang D. et al; HOST-REDUCE-POLYTECH-ACS investigators. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 2020; 396 (10257): 1079-1089
    CrossrefPubMedGoogle Scholar
  • 15 Wiviott SD, Desai N, Murphy SA. et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011; 108 (07) 905-911
    CrossrefPubMedGoogle Scholar
  • 16 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 17 Serebruany V, Rao SV, Silva MA. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31 (02) 227-235
    CrossrefPubMedGoogle Scholar
  • 18 Joo HJ, Ahn SG, Park JH. et al. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study. Sci Rep 2018; 8 (01) 1229
    CrossrefPubMedGoogle Scholar
  • 19 Lee JH, Ahn SG, Park B. et al. A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome. Korean J Intern Med (Korean Assoc Intern Med) 2015; 30 (05) 620-628
    CrossrefPubMedGoogle Scholar
  • 20 Sibbing D, Aradi D, Jacobshagen C. et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390 (10104): 1747-1757
    CrossrefPubMedGoogle Scholar
  • 21 Aradi D, Gross L, Trenk D. et al. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. Eur Heart J 2019; 40 (24) 1942-1951
    CrossrefPubMedGoogle Scholar
  • 22 Kang J, Park KW, Palmerini T. et al. Racial differences in ischaemia/bleeding risk trade-off during antiplatelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119 (01) 149-162
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Hahn JY, Song YB, Oh JH. et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial. JAMA 2019; 321 (24) 2428-2437
    CrossrefPubMedGoogle Scholar
  • 24 Kim BK, Hong SJ, Cho YH. et al; TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020; 323 (23) 2407-2416
    CrossrefPubMedGoogle Scholar
  • 25 Park MW, Kim CJ, Kim MC. et al. A Prospective, multicenter, randomized, open-label trial to compare efficacy and safety of clopidogrel vs. ticagrelor in stabilized patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALOS-AMI trial. EuroIntervention 2021; 16 (14) 1170-1176
    CrossrefPubMedGoogle Scholar
  • 26 Choi SY, Kim MH, Serebruany V. The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. Int J Cardiol 2016; 207: 128-131
    CrossrefPubMedGoogle Scholar
  • 27 Kwon TJ, Tantry US, Park Y. et al. Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. Thromb Haemost 2016; 115 (05) 979-992
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Amin AP, Bachuwar A, Reid KJ. et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 2013; 61 (21) 2130-2138
    CrossrefPubMedGoogle Scholar
  • 29 Riesmeyer JS, Salazar DE, Weerakkody GJ. et al. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol 2012; 52 (06) 789-797
    CrossrefPubMedGoogle Scholar
  • 30 Yun JE, Kim YJ, Park JJ. et al. Safety and Effectiveness of contemporary P2Y12 inhibitors in an East Asian population with acute coronary syndrome: A nationwide population-based cohort study. J Am Heart Assoc 2019; 8 (14) e012078
    CrossrefPubMedGoogle Scholar